DE69722053D1 - Azetidine - Google Patents

Azetidine

Info

Publication number
DE69722053D1
DE69722053D1 DE69722053T DE69722053T DE69722053D1 DE 69722053 D1 DE69722053 D1 DE 69722053D1 DE 69722053 T DE69722053 T DE 69722053T DE 69722053 T DE69722053 T DE 69722053T DE 69722053 D1 DE69722053 D1 DE 69722053D1
Authority
DE
Germany
Prior art keywords
alkyl
fluoro
cycloalkyl
alkoxy
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69722053T
Other languages
English (en)
Other versions
DE69722053T2 (de
Inventor
Alexander Roderick Mackenzie
Allan Patrick Marchington
Sandra Dora Meadows
Donald Stuart Middleton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Ltd
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Pfizer Research and Development Co NV SA filed Critical Pfizer Ltd
Publication of DE69722053D1 publication Critical patent/DE69722053D1/de
Application granted granted Critical
Publication of DE69722053T2 publication Critical patent/DE69722053T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69722053T 1996-01-27 1997-01-24 Azetidine Expired - Fee Related DE69722053T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9601697 1996-01-27
GBGB9601697.7A GB9601697D0 (en) 1996-01-27 1996-01-27 Therapeutic agents

Publications (2)

Publication Number Publication Date
DE69722053D1 true DE69722053D1 (de) 2003-06-26
DE69722053T2 DE69722053T2 (de) 2004-01-22

Family

ID=10787701

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69722053T Expired - Fee Related DE69722053T2 (de) 1996-01-27 1997-01-24 Azetidine

Country Status (11)

Country Link
US (2) US5741790A (de)
EP (1) EP0791592B1 (de)
JP (1) JP2918508B2 (de)
AT (1) ATE240952T1 (de)
CA (1) CA2195923C (de)
DE (1) DE69722053T2 (de)
DK (1) DK0791592T3 (de)
ES (1) ES2197295T3 (de)
GB (1) GB9601697D0 (de)
MX (1) MXPA97000695A (de)
PT (1) PT791592E (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
GB9812037D0 (en) * 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
GB9924141D0 (en) * 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
IT1255704B (it) * 1992-09-30 1995-11-10 Boehringer Mannheim Italia Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams

Also Published As

Publication number Publication date
CA2195923A1 (en) 1997-07-28
US6022971A (en) 2000-02-08
CA2195923C (en) 2001-05-29
DK0791592T3 (da) 2003-06-23
EP0791592A3 (de) 2000-05-17
US5741790A (en) 1998-04-21
JPH09208579A (ja) 1997-08-12
EP0791592B1 (de) 2003-05-21
DE69722053T2 (de) 2004-01-22
EP0791592A2 (de) 1997-08-27
GB9601697D0 (en) 1996-03-27
PT791592E (pt) 2003-09-30
ES2197295T3 (es) 2004-01-01
JP2918508B2 (ja) 1999-07-12
ATE240952T1 (de) 2003-06-15
MXPA97000695A (es) 2005-03-03

Similar Documents

Publication Publication Date Title
DE60329981D1 (de) Antipruriginosa
DE69331414D1 (de) Depsipeptide, herstellung und anwendung
ID24166A (id) Turunan piridazin baru dan obat-obatan yang mengandung hal yang sama sebagai ramuan efektif
DK0775132T3 (da) (Azetidin-1-ylalkyl)lactamer som tachykininantagonister
MXPA04001258A (es) Activador para el receptor d que responde al proliferador de peroxisoma.
DK0771794T3 (da) Oxygenholdige heterocykliske forbindelser
DK0842661T3 (da) Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning
DE69717970D1 (de) Chinolin carbonsaure-derivate und ihre salze
PT918776E (pt) Sintese total de acilfulvenos antitumorais
NO305174B1 (no) Heterocykliske forbindelser
YU71496A (en) Azetidines, their salts, application and process for preparation
DE69722053D1 (de) Azetidine
HRP20000508B1 (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
DK0962457T3 (da) Piperidoner som tachykininantagonister
NZ334214A (en) Processes and intermediates for preparing substituted chromanol derivatives useful in the treatment of LTB4-induced diseases such as inflammatory disorders
NO983439L (no) 1-(pyrazol-3-yl-etyl)-4-(indol-3-yl)-piperidin anvendt som medisin som virker på sentralnervesystemet
NO972943D0 (no) 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse
EP1142868A4 (de) Amidderivate
EP0807626A4 (de) N-hydroxyharnstoff-derivate
WO2000020399A3 (de) Verwendung von substituierten 5-hydroxypyrazolen, neue 5-hydroxypyrazole, verfahren zu deren herstellung, sowie sie enthaltende mittel
NO972942D0 (no) 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse
DK0661275T3 (da) 1-( alfa-Cyclopropyl-alfa-(substitueret oxy)-otolyl sulfamoyl) -3-(4,6-dimethoxy-2-pyrimidinyl) urinstoffer som herbicide midler.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee